Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?

2010 ◽  
Vol 127 (1-3) ◽  
pp. 10-18 ◽  
Author(s):  
R. Correa ◽  
H. Akiskal ◽  
W. Gilmer ◽  
A.A. Nierenberg ◽  
M. Trivedi ◽  
...  
1988 ◽  
Vol 33 (9) ◽  
pp. 788-792 ◽  
Author(s):  
G. William Macewan ◽  
Ronald A. Remick

One hundred and fourteen patients with a diagnosis of “treatment resistant depression” (TRD) were assessed and treated at a Mood Disorders Clinic. Diagnostically, 52 (45.6%) subjects met criteria for bipolar disorder, 49 (42.9%) for recurrent depression, and 13 (11.4%) patients did not fulfill diagnostic criteria for affective disorder which explained their treatment resistance. With appropriate, individualized treatment, 59 of 98 (60.2%) patients had complete symptom remission based on clinical and psychometric ratings (initial Ham-D 26.7, final Ham-D 5.9). Eighteen of 98 patients had partial remission (final Ham-D 15.9) with vigorous pharmacological interventions, and 8 subjects exhibited “absolute” TRD (final Ham-D 23.4). The results suggest the value of specialized mood disorder services. The partial and absolute TRD's were more likely to be older, received more Axis II diagnoses, and had previous histories of drug or alcohol abuse.


2009 ◽  
Vol 25 (2) ◽  
pp. 137-140 ◽  
Author(s):  
Sarah Kayser ◽  
Bettina Bewernick ◽  
Nikolai Axmacher ◽  
Thomas E. Schlaepfer

2021 ◽  
Vol 11 (4) ◽  
pp. 259-262
Author(s):  
Courtney Skriptshak ◽  
Ashley Reich

Abstract Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The manufacturer of intranasal esketamine states that it “has not been studied, and is not indicated, for patients with bipolar disorder.” Antidepressants are commonly associated with having the potential to induce rapid cycling in patients with bipolar disorder, though the mechanism is not fully understood. This case report demonstrates the potential safety of intranasal esketamine in combination with mood stabilizer therapy in a patient diagnosed with bipolar disorder without recent history of manic or hypomanic episodes.


Sign in / Sign up

Export Citation Format

Share Document